DeepBio

Seoul, South Korea  All South Korea companies → — Founded 2015
Series B — $17.9M+

Products

DeepBio DeepDx® Prostate
DeepBio
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.

See all 1 product →

About DeepBio

Deep Bio is a South Korean healthcare technology company specializing in AI-driven diagnostics for cancer, particularly focusing on improving accuracy and efficiency in pathology assessments. The company develops in-vitro diagnostic software as medical devices that leverage deep learning to assist pathologists in delivering more accurate cancer diagnoses and prognoses, ultimately aiming for better patient outcomes in oncology. Their flagship product, DeepDx® Prostate, analyzes digitized slide images of H&E-stained prostate specimens to detect and localize prostate cancer lesions, provide automated histological grading based on the Gleason system, and quantify tumor involvement.

Deep Bio’s solutions are designed to address critical challenges in traditional pathology, such as the shortage of pathologists and diagnostic inconsistencies. By integrating state-of-the-art AI into clinical workflows, Deep Bio aims to provide fast, accurate, and consistent diagnostic support. Their technology has been clinically validated and has received regulatory approvals in South Korea and CE-IVD marking for Europe, with ongoing efforts for global expansion.

Focus Areas

AI-powered digital pathology cancer diagnostics deep learning prostate cancer breast cancer bladder cancer

Business Intelligence

Key InvestorsMatter, Gencurix, Korea AI Startup 100, Albatross Investment, Daekyo Investment, DTI & Investment, Hyundai Investment, Sejong Venture Partners, Daesung Venture Investment, MG Investments, Shinhan Venture Investment, Cheil Electric, DB Financial Investment, The Wells Investment
PartnershipsPathAI, CancerX, Roche Navify Open Environment, Techcyte
Acquisitionsunknown
TechnologyDeep learning algorithms, cloud-native infrastructure, AI operating system (DeepBIO platform for biological sequence analysis - note: this may be a separate academic platform with a similar name, Deep Bio's core product is DeepDx®)
FDA Clearances0 (DeepDx® solutions are for Research Use Only (RUO) in the United States and not FDA cleared) cleared products (estimated)

Products by DeepBio

1 product in the directory

DeepBio DeepDx® Prostate
DeepBio
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.

Reviews & Opinions

No web reviews on file yet for DeepBio. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about DeepBio.

Loading videos...

Videos load interactively. If none appear, search YouTube for DeepBio →

View all on YouTube

Press & Coverage

EINPresswire.com
Deep Bio's AI Model for Prostate Cancer Assessment Validated by Researchers
An external validation study by Stanford Medicine published in the British Journal of Urology International confirmed the high accuracy and generalizability of DeepDx Prostate AI algorithm for detecting and grading prostate cancer on prostatectomy specimens.
2024-08
PRNewswire
Deep Bio Announces Launch of DeepDx Prostate in Switzerland, Paving the Way for European Expansion
Deep Bio launched its AI-powered prostate cancer diagnostic software, DeepDx Prostate, in Switzerland, marking a significant step towards expanding its presence across Europe.
2024-01
EINPresswire.com
Deep Bio And Techcyte Partner To Integrate AI-Powered Prostate Diagnostics And Frozen Section On Techcyte Fusion® Platform
Deep Bio partnered with Techcyte to integrate its AI algorithms for prostate and frozen section pathology into Techcyte's Fusion® digital pathology platform, expanding access to advanced AI capabilities for research applications.
2025-08
EIN News
Deep Bio Inc. integrates with PathAI, Inc.
Deep Bio's clinically validated AI technology was integrated with PathAI's advanced digital pathology platform, aiming to expand access to powerful diagnostic tools for prostate cancer.
2024-11
Meta Medical Solutions
Deep Bio Inc. partners with CancerX
Deep Bio is collaborating with CancerX on an initiative to transform cancer diagnosis and treatment landscapes.
2023-11
Korea Times
Deep Bio launches AI-diagnostic software on prostate cancer ..“grants certifications”
Deep Bio announced the release of its AI diagnostic software, DeepDx, for prostate cancer, which uses digitally scanned prostate biopsy images to detect cancer and generate pathology-like reports within 10 seconds.
2026-10
Deep Bio Official News
AI-driven diagnositc company, Deep Bio Inc. closes $5 Million USD in Series A
Deep Bio successfully closed a $5.6 million Series A funding round from various South Korean venture capital companies to accelerate the commercialization of its cancer diagnostic software products.
2025-05
Yahoo Finance
DeepBio becomes first Korean cancer diagnostic A.I. company to win CES Innovation Award
Deep Bio received a CES Innovation Award, becoming the first Korean AI cancer diagnostic company to achieve this recognition.
2023-11
No FAQs available yet for this company.

Related Companies

EXF Health, a vertical of Exafluence, focuses on enhancing healthcare organizations by strengthening their health IT infrastructure and improving their analytics and data maturity. The company leverages best-in-class AI/ML tools and techniques to add continuous value to all healthcare participants. For healthcare payers, EXF Health offers executive decision boards that provide actionable insights to track […]

EasyDocForms, developed and operated by AI Documentation LLC, provides HIPAA-compliant patient intake, charting, and scheduling software specifically designed for independent healthcare practices. The platform aims to eliminate the inefficiencies of traditional paper forms and generic software not tailored for specialty clinics. Physicians can upload their existing PDF forms, which are then converted into mobile-friendly, digital […]

Deal Run is a technology company that provides AI-powered tools primarily for real estate investors, specifically focusing on the disposition (selling) phase of wholesale real estate deals. The platform aims to streamline the process for investors by offering features such as property analysis, AI-estimated after-repair values (ARV), repair estimates based on property photos, and exit […]

CureCompanion is a telehealth technology company established in 2015 and headquartered in Austin, Texas. They specialize in building integrated hardware and software for virtual care, offering solutions like telemedicine carts, portable telemedicine kits, and remote patient monitoring home kits. These products run on the CureCompanion telehealth software platform, which is designed to go beyond basic […]

CortiCare is a leading provider of neuro telemetry and remote patient monitoring services, specializing in continuous EEG (cEEG) for hospitals, practices, and clinics. The company aims to make EEG monitoring accessible, affordable, and clinically reliable, addressing challenges such as staffing shortages and operational complexities that often hinder hospitals from providing continuous EEG. CortiCare’s services include […]

ClinicFlow is an AI-powered healthcare company that develops an artificial intelligence phone-answering platform specifically designed for surgical practices, including orthopedics, spine, and pain management. The platform aims to automate patient intake and triage, handling inbound calls 24/7 in multiple languages without wait times. It integrates with existing Electronic Medical Record (EMR) systems (such as Epic, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.